Jiajia Li
Bengbu, 233000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
ZMIZ1 promotes PAX6 ubiquitination through SMAD3 to drive the malignant progression of acute myeloid leukemia.
Journal: Molecular and cellular probes
Published: January 26, 2026
Phellinus igniarius targets HIF1A to regulate HK2 and inhibit metabolic reprogramming in acute myeloid leukemia.
Journal: Molecular and cellular probes
Published: January 15, 2026
Clinical Features and Prognosis Analysis of Acute Myeloid Leukemia in Children with DEK-CAN-Positive.
Journal: Clinical laboratory
Published: December 09, 2025
Clinical Characteristics and Diagnosis of Children t(8; 21)/AML1-ETO Positive Acute Myeloid Leukemia with Basophilic Granulocytosis.
Journal: Clinical laboratory
Published: November 12, 2025
METTL7A is a potential biomarker for the diagnosis and prognosis of acute myeloid leukemia.
Journal: Hematology (Amsterdam, Netherlands)
Published: July 24, 2025
MiR-155-5p Inhibits Multiple Myeloma Cell Malignancy and Tumorigenesis by Targeting JARID2 and Inactivating the TGFβ/SMAD2 Signaling.
Journal: Journal of biochemical and molecular toxicology
Published: March 20, 2025
Reduced-Dose versus Standard-Dose Emicizumab for Haemophilia A: A Retrospective Cohort Study.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: February 28, 2025
The IRF2-INPP4B Pathway Aggravates Acute Myeloid Leukemia
Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology
Published: February 17, 2025
SRSF12 is a prognostic biomarker involved in immune infiltration in acute myeloid leukemia.
Journal: Hematology (Amsterdam, Netherlands)
Published: October 28, 2024
Exosomal miR-140-3p produced by bone marrow stromal cells affects acute myeloid leukemia cell growth and apoptosis by targeting SUZ12.
Journal: Leukemia research
Published: October 03, 2024
Integrated bioinformatics and functional studies identify CDK9 as a potential prognostic biomarker and therapeutic target in AML.
Journal: Discover oncology
Published: September 29, 2024
Last Updated: 09/26/2026